Results 1 to 10 of about 106,447 (165)

Idiopathic pulmonary fibrosis: current diagnosis and treatment [PDF]

open access: yesJornal Brasileiro de Pneumologia, 2023
Idiopathic pulmonary fibrosis (IPF) is a devastating chronic lung disease without a clear recognizable cause. IPF has been at the forefront of new diagnostic algorithms and treatment developments that led to a shift in patients’ care in the past decade ...
Alexandre Franco Amaral   +2 more
doaj   +1 more source

Pulmonary Hypertension in Patients with Chronic Fibrosing Idiopathic Interstitial Pneumonias [PDF]

open access: yes, 2015
Background Pulmonary hypertension (PH) is a common finding in patients with chronic fibrosing idiopathic interstitial pneumonias (IIP). Little is known about the response to pulmonary vasodilator therapy in this patient population.
Behr, Juergen   +19 more
core   +15 more sources

Identifying potential biomarkers of idiopathic pulmonary fibrosis through machine learning analysis

open access: yesScientific Reports, 2023
Idiopathic pulmonary fibrosis (IPF) is the most common and serious type of idiopathic interstitial pneumonia, characterized by chronic, progressive, and low survival rates, while unknown disease etiology.
Zenan Wu   +7 more
doaj   +1 more source

IL-18 binding protein can be a prognostic biomarker for idiopathic pulmonary fibrosis.

open access: yesPLoS ONE, 2021
Idiopathic pulmonary fibrosis is a chronic, fibrosing interstitial pneumonia that presents with various clinical courses and progression ranging from rapid to slow.
Yu Nakanishi   +11 more
doaj   +1 more source

Impact of the new definition for pulmonary hypertension in patients with lung disease: an analysis of the United Network for Organ Sharing database

open access: yesPulmonary Circulation, 2021
The implications of the recent change in the definition of pulmonary hypertension on epidemiology and outcomes are not known. We sought to determine the percentage of patients with the two most common lung diseases that would be reclassified regarding ...
Steven D. Nathan   +7 more
doaj   +1 more source

Clinical relevance of circulating autoantibodies in idiopathic pulmonary fibrosis; A NAt hard to break

open access: yesFrontiers in Medicine, 2022
Patients with idiopathic pulmonary fibrosis are screened for circulating autoantibodies as part of the initial interstitial lung disease workup. Management of seropositive idiopathic pulmonary fibrosis is currently considered no different than that of ...
Paraskevi Kirgou   +8 more
doaj   +1 more source

Radiological findings based comparison of functional status in patients who have post-covid lung injury or idiopathic pulmonary fibrosis

open access: yesBMC Pulmonary Medicine, 2023
Background Following COVID-19 infection, some patients acquired lung injury and fibrosis. Idiopathic pulmonary fibrosis is characterized by lung fibrosis.
Deniz Kızılırmak   +3 more
doaj   +1 more source

The Role of DNA Damage and Repair in Idiopathic Pulmonary Fibrosis

open access: yesAntioxidants, 2022
The mortality rate of idiopathic pulmonary fibrosis (IPF) increases yearly due to ineffective treatment. Given that the lung is exposed to the external environment, it is likely that oxidative stress, especially the stimulation of DNA, would be of ...
Jiahui Zhu   +10 more
doaj   +1 more source

Comorbid Conditions in Idiopathic Pulmonary Fibrosis: Recognition and Management. [PDF]

open access: yes, 2017
Idiopathic pulmonary fibrosis (IPF), a fibrosing interstitial pneumonia of unknown etiology, primarily affects older adults and leads to a progressive decline in lung function and quality of life.
Collard, Harold R, Oldham, Justin M
core   +2 more sources

Recent advances in understanding idiopathic pulmonary fibrosis [PDF]

open access: yes, 2016
Despite major research efforts leading to the recent approval of pirfenidone and nintedanib, the dismal prognosis of idiopathic pulmonary fibrosis (IPF) remains unchanged.
Daccord, C, Maher, TM
core   +3 more sources

Home - About - Disclaimer - Privacy